Author:
Pingle Tanvi,Gupta Girdhari Lal
Reference75 articles.
1. The effect of statin therapy on lipoprotein-associated phospholipase A2 levels;Albert;Atherosclerosis,2005
2. Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East;Alshamiri;Int. J. Gen. Med.,2018
3. The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2;Blackie;Bioorg. Med. Chem. Lett.,2003
4. Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)-pyrimidones;Boyd;Bioorg. Med. Chem. Lett.,2002
5. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis;Bradley;J. Rhematol.,2005